New data presented at the 2025 San Antonio Breast Cancer Symposium indicates that Sapu Nano's Deciparticle nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics into sub-20 nanometer nanoparticles suitable for intravenous delivery. The platform successfully formulated macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides, demonstrating its versatility across multiple drug classes. Oncotelic Therapeutics, which owns 45% of Sapu Nano through its joint venture structure, reported that these findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities. The company stated this manufacturing infrastructure supports rapid translation to Phase 1 clinical trial supply, potentially accelerating the development timeline for new therapeutic candidates.
CEO Dr. Vuong Trieu said the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates. "Sapu003 represents the first of a broader pipeline," Trieu noted, referring to the initial candidate developed using this platform technology. The company's newsroom provides additional information about these developments at https://nnw.fm/OTLC. The ability to consistently formulate hydrophobic drugs—which typically have poor water solubility—into stable nanoparticles represents a significant advancement in drug delivery technology. Hydrophobic compounds constitute a substantial portion of promising therapeutic candidates, particularly in oncology, but their development has been hampered by formulation challenges that limit bioavailability and administration options.
By creating sub-20 nm nanoparticles suitable for intravenous delivery, the Deciparticle platform addresses key limitations in hydrophobic drug development. Smaller nanoparticle sizes generally offer advantages in tissue penetration and distribution, potentially improving therapeutic efficacy while maintaining the stability needed for clinical applications. The platform's compatibility with current Good Manufacturing Practice standards and ISO-5 cleanroom facilities indicates it could be rapidly deployed for clinical-stage development programs. The presentation at the San Antonio Breast Cancer Symposium, a premier oncology research conference, suggests the technology has particular relevance for cancer therapeutics. The ability to formulate diverse drug classes into nanoparticles could enable new combination therapies or reformulations of existing compounds with improved delivery characteristics. For more details on the specific findings presented, the complete data is available through the company's official announcement at https://nnw.fm/b0Qps.
This technological advancement comes as the pharmaceutical industry increasingly recognizes formulation challenges as critical bottlenecks in drug development. Platforms that can reliably address these challenges while maintaining manufacturing scalability could significantly impact the pipeline of new therapeutics, particularly in areas like oncology where hydrophobic compounds are prevalent. The modular nature of the Deciparticle platform suggests it could support multiple drug candidates simultaneously, potentially creating efficiencies in both development timelines and manufacturing processes.
